Bindu Rajan, MD
Internal Medicine · Glendale, AZNPI 1245287093
Payments from drug & device makers
Across 747 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$2K
- AbbVie$1K
- Amgen$1K
- Pfizer$1K
- Sanofi-aventis U.S. LLC$892
- plus $8K from 54 others
What the payments were for
- Consulting fees$4002%
- Food & beverage$15,35095%
- Education$3912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$494
- FARXIGA$492
- Kerendia$354
- Ozempic$348
- Edwards SAPIEN 3 Transcatheter Heart Valve$148
- SAPIEN 3 Ultra RESILIA$143
- AIRSUPRA$126
- TRELEGY ELLIPTA$125
- SHINGRIX$125
- Repatha$122
- EVENITY$119
- Vascepa$116
- RYBELSUS$116
- VRAYLAR$115
- TOUJEO$114
- Superion Indirect Decompression System$112
- BYDUREON$112
- SYMBICORT$112
- XIFAXAN$108
- INJECTAFER$103
How this compares
$16,141 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $116,921 |
| EliquisApixaban | 73 | $83,265 |
| FarxigaDapagliflozin Propanediol | 52 | $59,577 |
| JardianceEmpagliflozin | 23 | $34,827 |
| TrulicityDulaglutide | 15 | $24,752 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $18,762 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $16,829 |
| Repatha SureclickEvolocumab | 25 | $16,593 |
| MounjaroTirzepatide | 11 | $10,537 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $9,331 |
| Rosuvastatin Calcium | 391 | $5,771 |
| Levothyroxine Sodium | 476 | $5,638 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 24 | $5,372 |
| Losartan Potassium | 448 | $5,203 |
| Atorvastatin Calcium | 443 | $4,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,584 | $116,92170 claims |
| PfizerEliquis | $1,088 | $83,26573 claims |
| AstraZenecaFarxiga, Symbicort | $2,022 | $68,90877 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $593 | $35,28926 claims |
| Boehringer IngelheimJardiance | $356 | $34,82723 claims |
| GSKTrelegy Ellipta, Shingrix | $651 | $24,13442 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $892 | $16,82915 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $5,638476 claims |
| AbbVieSynthroid | $1,499 | $3,37749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Glendale
- Gurdev SinghGlendale$649K
- Michael CastroGlendale$156K
- Christine HarterGlendale$127K
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.